$1.09 Billion is the total value of Casdin Capital, LLC's 32 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
CDXS | CODEXIS INC | $81,130,000 | -99.9% | 5,073,780 | 0.0% | 7.46% | +3.6% | |
BPMC | BLUEPRINT MEDICINES CORP | $75,303,000 | -99.9% | 940,000 | 0.0% | 6.92% | -3.1% | |
BOLD | AUDENTES THERAPEUTICS INC | $51,462,000 | -99.8% | 860,000 | 0.0% | 4.73% | +89.3% | |
FATE | FATE THERAPEUTICS INC | $49,904,000 | -99.9% | 2,550,000 | 0.0% | 4.59% | +12.0% | |
GBT | GLOBAL BLOOD THERAPEUTICS IN | $23,847,000 | -99.8% | 300,000 | 0.0% | 2.19% | +45.6% | |
ILMN | ILLUMINA INC | $19,904,000 | -99.9% | 60,000 | 0.0% | 1.83% | -3.1% | |
GNMK | GENMARK DIAGNOSTICS INC | $16,186,000 | -99.9% | 3,365,000 | 0.0% | 1.49% | -29.5% | |
ADPT | ADAPTIVE BIOTECHNOLOGIES COR | $13,857,000 | -99.9% | 463,125 | 0.0% | 1.27% | -14.0% | |
SGMO | SANGAMO THERAPEUTICS INC | $12,178,000 | -99.9% | 1,455,000 | 0.0% | 1.12% | -17.8% | |
TWST | TWIST BIOSCIENCE CORP | $6,300,000 | -99.9% | 300,000 | 0.0% | 0.58% | -21.9% | |
TPTX | TURNING POINT THERAPEUTICS I | $4,672,000 | -99.8% | 75,000 | 0.0% | 0.43% | +47.3% | |
STOK | STOKE THERAPEUTICS INC | $3,682,000 | -99.9% | 130,000 | 0.0% | 0.34% | +17.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
CODEXIS INC | 22 | Q3 2023 | 8.1% |
SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2024-05-02 |
SC 13G | 2024-04-18 |
SC 13D/A | 2024-04-08 |
4 | 2024-03-28 |
3 | 2024-03-25 |
4 | 2024-03-25 |
4 | 2024-03-20 |
SC 13D/A | 2024-03-20 |
4 | 2024-03-06 |
4 | 2024-03-06 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.